Immunovant, Inc. (IMVT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$39.25+0.33%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IMVT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
IMVT — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, Immunovant, Inc. (“the Company”) issued a press release announcing its financial results for its fiscal first quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1…
Why it matters: If earnings miss again, it shows ongoing problems. This may hurt investor trust.
Worry ifCompany reports another earnings miss for Q1 2026.
Less concerning ifCompany meets or exceeds earnings expectations for Q1 2026.
Why it matters: Higher R&D costs show ongoing investment in clinical trials. This is important for growth.
Watch forR&D costs will go over $150 million next quarter due to clinical work.
Also watch forR&D costs drop below $130 million. This suggests less clinical activity.
Why it matters: Cash updates will show if the company can fund its ongoing trials and operations. This affects investor confidence.
Watch forCash position is over $800 million before earnings.
Also watch forCash position drops below $800 million before earnings.
Why it matters: A significant change in cash could affect the launch plans for IMVT-1402. This is critical for funding ongoing trials.
Worry ifCash and cash equivalents increase or stay above $797.8 million, supporting launch plans.
Less concerning ifCash and cash equivalents fall below $700 million. This raises concerns about funding.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$134 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $448 loss on $10,000 · 4.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,719 loss on $10,000 · 17.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A drop in revenue growth could signal a weakening position in the healthcare sector.
Worry ifRevenue growth reported below the median for the sector in the next quarter.
Less concerning ifRevenue growth remains above the median for the sector.
Why it matters: Earnings results will show the company's financial health and trial impacts.
Watch forEarnings report shows a reduction in net loss compared to previous quarters.
Also watch forEarnings report shows an increase in net loss compared to previous quarters.
Why it matters: Updates on IMVT-1402 in Graves' disease could signal progress toward a potential launch. This is a key priority for the company.
Supportive ifUpdates on trials for IMVT-1402 in Graves' disease will come in 2027.
Worry ifNo updates are shared or timelines are delayed.
Why it matters: If healthcare revenue growth speeds up, it may help Immunovant's performance. This can signal a better environment for the company.
Supportive ifHealthcare revenue growth accelerates back to above 10% year over year.
Worry ifHealthcare revenue growth remains below 5% year over year.
Why it matters: If R&D costs go up a lot, it may show financial issues. This could hurt investor trust.
Worry ifR&D expenses reported at or below $150 million for Q3.
Less concerning ifR&D expenses reported above $150 million for Q3.
Why it matters: Data from this trial may show how well the drug works. This could help get future approvals.
Supportive ifTopline data from the proof-of-concept trial in CLE is reported as positive.
Worry ifTopline data from the trial shows no meaningful response or delays in reporting.
Why it matters: News on this program may show the drug's promise in a hard market.
Supportive ifManagement shares good news about the IMVT-1402 D2T RA program.
Worry ifManagement reports problems or bad news in the D2T RA program.
Why it matters: A big drop in cash could hurt development plans and raise funding worries.
Worry ifCash and cash equivalents are over $700 million. This helps with ongoing development.
Less concerning ifCash and cash equivalents drop below $700 million. This raises worries about money stability.